Heparin-Induced Thrombocytopenia (HIT)
An immune reaction to heparin that triggers clotting
Quick Facts
- Type: Drug reaction / blood disorder
- Cause: Immune response to heparin
- Key paradox: Low platelets but high clot risk
- Action needed: Stop heparin immediately, use alternative blood thinner
Overview
Heparin-induced thrombocytopenia (HIT) is a serious complication of treatment with heparin, a commonly used blood thinner. In HIT, the immune system makes antibodies that react to heparin combined with a protein released by platelets. This reaction lowers the platelet count (thrombocytopenia) but, unlike most causes of low platelets, it strongly increases the risk of dangerous blood clots rather than bleeding.
HIT typically develops about 5 to 10 days after heparin is started, though it can appear sooner in someone recently exposed to heparin. Because the clots it causes can be limb-threatening or life-threatening, HIT is a medical emergency that requires prompt recognition, immediate stopping of all heparin, and a switch to a different type of blood thinner.
Symptoms
The hallmark of HIT is a falling platelet count, often detected on routine blood tests, together with signs of new clotting. Possible features include:
- A drop in the platelet count, typically 5 to 10 days after starting heparin
- A new blood clot in a vein or artery (such as a leg clot or a clot in the lungs)
- Painful, swollen limb from a deep vein clot
- Skin changes or sores at heparin injection sites
- In severe cases, clots affecting limbs or organs
Unlike many low-platelet conditions, bleeding is uncommon; the main danger is clotting. Any new clot in someone receiving heparin should raise suspicion of HIT.
Causes
HIT is an immune (antibody-driven) reaction, not a direct toxic effect of heparin.
- Antibody formation: The body makes antibodies against a complex of heparin and a platelet protein called platelet factor 4.
- Platelet activation: These antibodies activate platelets, causing them to clump and form clots while also being used up, which lowers the platelet count.
- Heparin type: The risk is higher with unfractionated heparin than with low molecular weight heparin, and varies with the situation in which heparin is used.
Risk Factors
- Treatment with unfractionated heparin (higher risk than low molecular weight heparin)
- Recent major surgery, particularly cardiac or orthopedic surgery
- Longer duration of heparin exposure
- Previous exposure to heparin within the past several months
Diagnosis
Diagnosis combines clinical judgment with laboratory tests, because results can take time and treatment often cannot wait.
- Clinical scoring: Doctors use a structured assessment of the timing and degree of the platelet drop, the presence of new clots, and whether other causes are likely.
- Antibody blood tests: Tests that detect the HIT antibodies, with confirmatory functional tests in specialized laboratories.
- Imaging: Ultrasound or other scans to look for clots when one is suspected.
Because of the danger, treatment is often started based on clinical suspicion before all test results return.
Treatment
Prompt treatment is essential to prevent clotting complications.
- Stop all heparin immediately: Including heparin flushes and heparin-coated devices.
- Start a non-heparin blood thinner: Alternative anticoagulants that do not contain heparin are used to manage the strong clotting risk.
- Avoid platelet transfusions: These are generally not given, as they may worsen clotting, unless there is significant bleeding.
- Treat any clots: Continue anticoagulation for an appropriate period if a clot has formed.
- Document the reaction: The person should avoid heparin in the future and be informed of the reaction.
Prevention
- Using heparin only when needed and for the shortest effective time
- Choosing low molecular weight heparin over unfractionated heparin where appropriate, as it carries lower risk
- Monitoring platelet counts during heparin treatment in higher-risk situations
- Recording a known HIT reaction clearly so heparin is avoided in future care
When to See a Doctor
HIT usually develops in people already in hospital or under medical care, where blood counts are monitored. Seek urgent medical attention if, while taking or recently having taken heparin, you notice:
- A new painful, swollen leg or arm
- Sudden shortness of breath or chest pain (possible clot in the lungs)
- Skin sores or color changes at injection sites
- Signs of poor circulation in a limb, such as coldness, pallor, or severe pain
These can be signs of dangerous clotting and require immediate care.
Frequently Asked Questions
Why does HIT cause clots when platelets are low?
In HIT, antibodies activate platelets, making them clump together and form clots while also being consumed, which lowers the count. So even though the platelet number falls, the activated platelets drive dangerous clotting rather than bleeding.
When does heparin-induced thrombocytopenia develop?
It typically appears about 5 to 10 days after heparin is started. In someone who has been exposed to heparin within the past few months, it can develop more quickly because the antibodies may already be present.
Is HIT an emergency?
Yes. The clots HIT causes can threaten limbs and be life-threatening, so it is treated as a medical emergency. All heparin must be stopped immediately and replaced with a non-heparin blood thinner, often before confirmatory tests return.
How is HIT treated?
Treatment means stopping all heparin right away, including flushes and coated devices, and starting an alternative non-heparin blood thinner to control the clotting risk. Platelet transfusions are generally avoided, and any clots are treated with continued anticoagulation.
Can someone with HIT ever receive heparin again?
People who have had HIT are advised to avoid heparin in the future, and the reaction should be clearly documented in their medical records so it is not given again. Alternative blood thinners are used when anticoagulation is needed.
References
- MedlinePlus, U.S. National Library of Medicine. Drug-induced thrombocytopenia.
- American Society of Hematology. Heparin-induced thrombocytopenia.
- National Heart, Lung, and Blood Institute (NHLBI). Thrombocytopenia.